Comanche lines up trial for preeclampsia siRNA with Moderna, Medicines Company vets and GV backing
A new siRNA biotech from Moderna and Medicines Company veterans is nearing the clinic as it looks to address rising maternal health risks and reduce a life-threatening complication in pregnancies that impacts millions of women like Allyson Felix, America’s most-decorated track Olympian.
The startup, Comanche Biopharma, has been operating mostly in stealth mode until this point, and is developing a one-time therapy that it hopes will work for about 90% of preeclampsia cases, said chief medical officer Allison August, a former VP of clinical development for infectious diseases at Moderna. Felix was also recently named a board member.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters